Ligand Pharmaceuticals Statistics
Share Statistics
Ligand Pharmaceuticals has 18.90M shares outstanding. The number of shares has increased by 4.78% in one year.
| Shares Outstanding | 18.90M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.7% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 18.47M |
| Failed to Deliver (FTD) Shares | 252 |
| FTD / Avg. Volume | 0.22% |
Short Selling Information
The latest short interest is 918.63K, so 4.86% of the outstanding shares have been sold short.
| Short Interest | 918.63K |
| Short % of Shares Out | 4.86% |
| Short % of Float | 4.98% |
| Short Ratio (days to cover) | 10.31 |
Valuation Ratios
The PE ratio is 23.69 and the forward PE ratio is 20.19. Ligand Pharmaceuticals's PEG ratio is 0.45.
| PE Ratio | 23.69 |
| Forward PE | 20.19 |
| PS Ratio | 9.41 |
| Forward PS | 12.2 |
| PB Ratio | 1.76 |
| P/FCF Ratio | -289.19 |
| PEG Ratio | 0.45 |
Enterprise Valuation
Ligand Pharmaceuticals has an Enterprise Value (EV) of 1.22B.
| EV / Earnings | 23.37 |
| EV / Sales | 9.28 |
| EV / EBITDA | 11.98 |
| EV / EBIT | 102.05 |
| EV / FCF | -285.26 |
Financial Position
The company has a current ratio of 14.15, with a Debt / Equity ratio of 0.
| Current Ratio | 14.15 |
| Quick Ratio | 12.72 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 18.2 |
Financial Efficiency
Return on equity (ROE) is 0.07% and return on capital (ROIC) is 1.43%.
| Return on Equity (ROE) | 0.07% |
| Return on Assets (ROA) | 0.07% |
| Return on Capital (ROIC) | 1.43% |
| Revenue Per Employee | 2.26M |
| Profits Per Employee | 899.21K |
| Employee Count | 58 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 1.46 |
Taxes
| Income Tax | 9.84M |
| Effective Tax Rate | 0.15 |
Stock Price Statistics
The stock price has increased by 73.67% in the last 52 weeks. The beta is 0.9, so Ligand Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.9 |
| 52-Week Price Change | 73.67% |
| 50-Day Moving Average | 113.34 |
| 200-Day Moving Average | 94.28 |
| Relative Strength Index (RSI) | 44.8 |
| Average Volume (20 Days) | 113.20K |
Income Statement
In the last 12 months, Ligand Pharmaceuticals had revenue of $131.31M and earned $52.15M in profits. Earnings per share was $3.02.
| Revenue | 131.31M |
| Gross Profit | 96.27M |
| Operating Income | 11.94M |
| Net Income | 52.15M |
| EBITDA | 101.73M |
| EBIT | 11.94M |
| Earnings Per Share (EPS) | 3.02 |
Balance Sheet
The company has $22.95M in cash and $6.17M in debt, giving a net cash position of $16.79M.
| Cash & Cash Equivalents | 22.95M |
| Total Debt | 6.17M |
| Net Cash | 16.79M |
| Retained Earnings | 503.02M |
| Total Assets | 954.87M |
| Working Capital | 284.62M |
Cash Flow
In the last 12 months, operating cash flow was $49.58M and capital expenditures -$3.52M, giving a free cash flow of -$4.27M.
| Operating Cash Flow | 49.58M |
| Capital Expenditures | -3.52M |
| Free Cash Flow | -4.27M |
| FCF Per Share | -0.25 |
Margins
Gross margin is 73.31%, with operating and profit margins of 9.09% and 39.72%.
| Gross Margin | 73.31% |
| Operating Margin | 9.09% |
| Pretax Margin | 48.48% |
| Profit Margin | 39.72% |
| EBITDA Margin | 77.47% |
| EBIT Margin | 9.09% |
| FCF Margin | -3.25% |
Dividends & Yields
LGND does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 2.58% |
| FCF Yield | -0.19% |
Analyst Forecast
The average price target for LGND is $143, which is 22.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $143 |
| Price Target Difference | 22.3% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Nov 2, 2022. It was a forward split with a ratio of 1603:1000.
| Last Split Date | Nov 2, 2022 |
| Split Type | forward |
| Split Ratio | 1603:1000 |
Scores
| Altman Z-Score | 12.44 |
| Piotroski F-Score | 4 |